KathrynAnnGoldMD

Oncology • La Jolla, CA

Hematologic Oncology

Associate Professor, University of California San Diego

Join to view full profile

Dr. Gold is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gold's full profile

Already have an account?

Office
3855 Health Sciences Dr # 987
La Jolla, CA 92093
Phone+1 858-822-5182

Fax+1 858-822-6186

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
Washington University in St. Louis School of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2015 - 2025
TX State Medical License 2008 - 2024
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2018 Jun 06
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

7 citations
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
William N William Jr, Jianjun Zhang, Xin Zhao, Edwin R Parra, Naohiro Uraoka
Cancer. 2023-03-01
8 citations
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Michael J Dennis, Assuntina G Sacco, Yuchen Qi, Julie Bykowski, Emily Pittman
Oral Oncology. 2022-12-01
11 citations
Clinicopathologic and molecular characteristics of-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.
Li Yu, Lyudmila Bazhenova, Kathryn Gold, Lisa Tran, Van Hilburn
Translational Lung Cancer Research. 2022-03-01

Press Mentions

COVID-19 Pandemic Is Driving up Rate of Late-Stage Cancer Diagnoses, UCSD Researchers SayFebruary 17th, 2022
COVID Pandemic Driving up Late-Stage Cancer Rates, UCSD FindsFebruary 15th, 2022
Increase in Late-Stage Cancer Diagnoses After PandemicFebruary 15th, 2022